Contributors |
|
ix | |
Preface |
|
xi | |
|
1 The evolution and history of gene editing technologies |
|
|
1 | (62) |
|
|
|
|
2 | (4) |
|
2 Gene editing technologies |
|
|
6 | (23) |
|
3 Applications of gene editing technologies |
|
|
29 | (12) |
|
4 Drawbacks of gene editing technologies |
|
|
41 | (2) |
|
5 Ethics of gene editing technologies |
|
|
43 | (4) |
|
|
47 | (1) |
|
|
48 | (15) |
|
2 CRISPR-Cas9: A fascinating journey from bacterial immune system to human gene editing |
|
|
63 | (22) |
|
|
|
64 | (3) |
|
2 CRISPR-Cas9: An exciting journey from bacteria to human |
|
|
67 | (8) |
|
3 Therapeutic applications of the CRISPR-Cas9: Technology for precise gene therapy |
|
|
75 | (2) |
|
4 Therapeutic applications of the CRISPR-Cas9: Problems and challenges |
|
|
77 | (2) |
|
|
79 | (1) |
|
|
80 | (5) |
|
3 Modification of Cas9, gRNA and PAM: Key to further regulate genome editing and its applications |
|
|
85 | (14) |
|
|
|
|
|
|
|
|
|
|
|
86 | (1) |
|
|
87 | (4) |
|
3 Structural based re-designing of Cas9 |
|
|
91 | (2) |
|
4 Customizing PAM specificity by leveraging directed evolution |
|
|
93 | (1) |
|
5 Guide RNA (gRNA) engineering |
|
|
94 | (2) |
|
|
96 | (1) |
|
|
96 | (1) |
|
|
97 | (1) |
|
|
97 | (2) |
|
4 CRISPR/dCas system as the modulator of gene expression |
|
|
99 | (24) |
|
|
|
|
100 | (1) |
|
|
101 | (1) |
|
|
102 | (2) |
|
|
104 | (2) |
|
5 Epigenome engineering and CRISPRi/a |
|
|
106 | (6) |
|
6 dCas9 toolboxes beyond CRISPRi/a |
|
|
112 | (2) |
|
|
114 | (1) |
|
|
115 | (1) |
|
|
115 | (1) |
|
|
115 | (8) |
|
5 CRISPR-Cas system, antibiotic resistance and virulence in bacteria: Through a common lens |
|
|
123 | (52) |
|
|
|
|
|
|
126 | (2) |
|
2 Bacterial CRISPR-Cas system |
|
|
128 | (2) |
|
3 Bacterial antimicrobial resistance |
|
|
130 | (5) |
|
4 Interference of CRISPR-Cas with bacterial antimicrobial resistance |
|
|
135 | (9) |
|
5 Association of CRISPR-Cas with bacterial virulence |
|
|
144 | (4) |
|
6 Detection of CRISPR-Cas system in bacteria |
|
|
148 | (4) |
|
7 Applications of CRISPR-Cas for controlling antimicrobial resistance and virulence |
|
|
152 | (14) |
|
|
166 | (1) |
|
|
166 | (1) |
|
|
167 | (1) |
|
|
167 | (8) |
|
6 Trends in CRISPR-Cas9 technology application in cancer |
|
|
175 | (18) |
|
|
|
|
175 | (1) |
|
2 Genome-wide CRISPR-Cas9 library screening in cancer cells |
|
|
176 | (3) |
|
3 Potential clinical application of CRISPR in cancer therapy |
|
|
179 | (3) |
|
4 Quality control and bioinformatics of CRISPR guide design |
|
|
182 | (3) |
|
5 Perils of CRISPR-Cas technology |
|
|
185 | (2) |
|
6 Conclusion and future perspective |
|
|
187 | (1) |
|
|
187 | (1) |
|
|
187 | (6) |
|
7 Mitochondrial DNA modification by CRISPR/Cas system: Challenges and future direction |
|
|
193 | (20) |
|
|
|
|
194 | (4) |
|
2 Mitochondrial DNA modification in disease condition |
|
|
198 | (5) |
|
|
203 | (2) |
|
4 Implementation of CRISPR/Cas in mitochondrial DNA modification |
|
|
205 | (1) |
|
|
206 | (2) |
|
|
208 | (3) |
|
|
211 | (2) |
|
8 Immune responses to CRISPR-Cas protein |
|
|
213 | (18) |
|
|
|
214 | (1) |
|
2 The overview of CRISPR-Cas9 technology |
|
|
215 | (1) |
|
3 The structure of CRISPR-Cas9 |
|
|
215 | (1) |
|
4 Challenges associated with the implication of CRISPR-CAS9 technology |
|
|
216 | (2) |
|
5 Immunogenicity of Cas9 proteins |
|
|
218 | (8) |
|
6 Future direction and strategies to deal with immunogenicity |
|
|
226 | (1) |
|
|
227 | (1) |
|
|
227 | (1) |
|
|
227 | (4) |
|
9 Application of CRISPR-Cas systems in neuroscience |
|
|
231 | (34) |
|
|
|
1 A basic overview of the CRISPR-Cas system |
|
|
232 | (2) |
|
2 Delivery and expression mechanisms in applications of CRISPR-Cas9 based disruption of genes in the mammalian CNS |
|
|
234 | (10) |
|
3 Gene editing with CRISPR-Cas9 in neurons |
|
|
244 | (5) |
|
4 The repurposed CRISPR-Cas9: Nuclease deficient-cas9 (dcas9) and neuroscience |
|
|
249 | (8) |
|
5 RNA-targeting with CRISPR in the neuron |
|
|
257 | (2) |
|
6 Perspectives and concluding remarks |
|
|
259 | (2) |
|
|
261 | (4) |
Index |
|
265 | |